Have a look at a recent paper by an osteopath with strong anti-industry sentiment who nevertheless manages to put together a study that systematically (and mostly fairly) examines the biases evident among published reviews of rimonabant. I say “mostly fairly”, because I found the editorializing to be all over the place, an anti-industry data dump if you will, [...]
According to the Pharma Marketing Blog, which gets its data from MEd Ad News and Nielsen, the industry spent over $5 billion USD globally in 2007 on DTC advertising (IMS Health pegs it at just under $5 Billlion). The US is the major portion of this spend. IMS Health puts the 2007 US DTC spend at [...]
For the last few years, I have held an opinion contrary to most of my colleagues in the industry–that sponsors should be required to conduct large (simple) safety studies prior to marketing authorization for drugs intended to be used chronically in large, especially elderly, populations. Such studies would have as their primary goal a safety evaluation including [...]
You might have caught the editorial published today on PLoS Medicine by Fugh-Berman and Melnick, which decries rampant, greed-driven off-label promotion by pharmaceutical marketers. They suggest that the US government step in with tighter reigns and resist “gutting” current restrictions against off-label promotion.
The authors make their argument without providing evidence that off-label use of drugs [...]
You might have caught Pharmalot’s piece on the recently passed Mass. legislation that will codify pharmaceutical marketing to healthcare practitioners. The article describes Lilly CEO John Lechleiter’s response to the measure, which was harsh, essentially threatening to caught off Mass. from future Lilly R&D investments:
Such work is the backbone of research and development in biotechnology and [...]
